US stock futures muted with Jackson Hole, retail earnings on tap
In a recent transaction, Jeffrey S. Heier, the Chief Scientific Officer of Ocular Therapeutix, Inc. (NASDAQ:OCUL), a company with a market capitalization of $1.06 billion, sold 3,061 shares of the company’s common stock. The shares were sold at a weighted average price of $6.87, amounting to a total transaction value of $21,029. This sale was part of a pre-established plan to cover tax withholding obligations related to the vesting of restricted stock units. Following this transaction, Heier holds 265,998 shares directly. The shares were sold in multiple transactions, with prices ranging from $6.78 to $6.99. According to InvestingPro data, the stock’s RSI suggests oversold territory, and the company maintains strong liquidity with a current ratio of 13.01. With earnings scheduled for March 6, investors can access comprehensive analysis and additional insights through InvestingPro’s detailed research reports.
In other recent news, Ocular Therapeutix has announced a revised compensation package for its CEO, Pravin Dugel, M.D., following his promotion to President and CEO in April 2024. The Board of Directors set his annual base salary at $819,200 with a bonus target of 75% for 2025, alongside significant long-term equity awards contingent on stock price performance. Meanwhile, Raymond (NSE:RYMD) James maintained a Strong Buy rating with a $19.00 price target, noting potential advantages for Ocular’s Axpaxli in treating diabetic macular edema. The company has made significant progress in its clinical trials for Axpaxli, particularly in the Phase 3 SOL-1 trial for wet age-related macular degeneration, which has completed patient randomization.
H.C. Wainwright also reaffirmed a Buy rating with a $15.00 price target, citing strong interest in Axpaxli as evidenced by rapid trial enrollment. The SOL-1 trial’s topline results are anticipated in the fourth quarter of 2025, with the SOL-R trial enrollment ongoing. Additionally, Baird maintained an Outperform rating and a $17.00 price target, emphasizing the potential of Axpaxli in the wet AMD (NASDAQ:AMD) market. The firm’s confidence is bolstered by the company’s commitment to advancing clinical programs and the accelerated enrollment in Phase 3 trials. These developments highlight Ocular Therapeutix’s ongoing efforts to expand its portfolio in the ophthalmology therapeutic space.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.